Cargando…
A phase Ib trial of mivavotinib (TAK-659), a dual SYK/FLT3 inhibitor, in patients with relapsed/refractory acute myeloid leukemia
Mivavotinib (TAK-659) is an investigational type 1 tyrosine kinase inhibitor with dual activity against spleen tyrosine kinase (SYK) and FMS-like tyrosine kinase 3 (FLT3). We conducted a phase Ib study to investigate the safety, tolerability, and efficacy of mivavotinib in patients with refractory a...
Autores principales: | , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Fondazione Ferrata Storti
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9973464/ https://www.ncbi.nlm.nih.gov/pubmed/36226495 http://dx.doi.org/10.3324/haematol.2022.281216 |
_version_ | 1784898529632714752 |
---|---|
author | Pratz, Keith W. Kaplan, Jason Levy, Moshe Bixby, Dale Burke, Patrick W. Erba, Harry Wise-Draper, Trisha M. Roboz, Gail J. Papadantonakis, Nikolaos Rajkhowa, Trivikram Hernandez, Daniela Dobler, Iwona Gregory, Richard C. Li, Cheryl Wang, Shining Stumpo, Kate Kannan, Karuppiah Miao, Harry Levis, Mark |
author_facet | Pratz, Keith W. Kaplan, Jason Levy, Moshe Bixby, Dale Burke, Patrick W. Erba, Harry Wise-Draper, Trisha M. Roboz, Gail J. Papadantonakis, Nikolaos Rajkhowa, Trivikram Hernandez, Daniela Dobler, Iwona Gregory, Richard C. Li, Cheryl Wang, Shining Stumpo, Kate Kannan, Karuppiah Miao, Harry Levis, Mark |
author_sort | Pratz, Keith W. |
collection | PubMed |
description | Mivavotinib (TAK-659) is an investigational type 1 tyrosine kinase inhibitor with dual activity against spleen tyrosine kinase (SYK) and FMS-like tyrosine kinase 3 (FLT3). We conducted a phase Ib study to investigate the safety, tolerability, and efficacy of mivavotinib in patients with refractory and/or relapsed (R/R) acute myeloid leukemia (AML). Both daily (QD) and twice daily (BID) dosing regimens were evaluated. A total of 43 patients were enrolled, and there were 5 complete responses (4 with incomplete count recovery). In the QD dosing regimen, the maximum tolerated dose (MTD) was not reached up to 160 mg QD per protocol; 140 mg QD was identified as the recommended phase II dose. In the BID dosing regimen, the MTD was 60 mg BID. Thirty patients (70%) experienced a bleeding event on study; the majority were grades 1 or 2, were resolved without mivavotinib modification, and were not considered related to study treatment. Eleven patients (26%) experienced grade ≥3 bleeding events, which were observed most frequently with the 80 mg BID dose. We conducted platelet aggregation studies to investigate the potential role of mivavotinib-mediated SYK inhibition on platelet function. The bleeding events observed may have been the result of several confounding factors, including AML disease status, associated thrombocytopenia, and high doses of mivavotinib. Overall, these findings indicate that the activity of mivavotinib in R/R AML is modest. Furthermore, any future clinical investigation of this agent should be undertaken with caution, particularly in thrombocytopenic patients, due to the potential bleeding risk of SYK inhibition. ClinicalTrials.gov: NCT02323113. |
format | Online Article Text |
id | pubmed-9973464 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Fondazione Ferrata Storti |
record_format | MEDLINE/PubMed |
spelling | pubmed-99734642023-03-01 A phase Ib trial of mivavotinib (TAK-659), a dual SYK/FLT3 inhibitor, in patients with relapsed/refractory acute myeloid leukemia Pratz, Keith W. Kaplan, Jason Levy, Moshe Bixby, Dale Burke, Patrick W. Erba, Harry Wise-Draper, Trisha M. Roboz, Gail J. Papadantonakis, Nikolaos Rajkhowa, Trivikram Hernandez, Daniela Dobler, Iwona Gregory, Richard C. Li, Cheryl Wang, Shining Stumpo, Kate Kannan, Karuppiah Miao, Harry Levis, Mark Haematologica Article - Acute Myeloid Leukemia Mivavotinib (TAK-659) is an investigational type 1 tyrosine kinase inhibitor with dual activity against spleen tyrosine kinase (SYK) and FMS-like tyrosine kinase 3 (FLT3). We conducted a phase Ib study to investigate the safety, tolerability, and efficacy of mivavotinib in patients with refractory and/or relapsed (R/R) acute myeloid leukemia (AML). Both daily (QD) and twice daily (BID) dosing regimens were evaluated. A total of 43 patients were enrolled, and there were 5 complete responses (4 with incomplete count recovery). In the QD dosing regimen, the maximum tolerated dose (MTD) was not reached up to 160 mg QD per protocol; 140 mg QD was identified as the recommended phase II dose. In the BID dosing regimen, the MTD was 60 mg BID. Thirty patients (70%) experienced a bleeding event on study; the majority were grades 1 or 2, were resolved without mivavotinib modification, and were not considered related to study treatment. Eleven patients (26%) experienced grade ≥3 bleeding events, which were observed most frequently with the 80 mg BID dose. We conducted platelet aggregation studies to investigate the potential role of mivavotinib-mediated SYK inhibition on platelet function. The bleeding events observed may have been the result of several confounding factors, including AML disease status, associated thrombocytopenia, and high doses of mivavotinib. Overall, these findings indicate that the activity of mivavotinib in R/R AML is modest. Furthermore, any future clinical investigation of this agent should be undertaken with caution, particularly in thrombocytopenic patients, due to the potential bleeding risk of SYK inhibition. ClinicalTrials.gov: NCT02323113. Fondazione Ferrata Storti 2022-10-13 /pmc/articles/PMC9973464/ /pubmed/36226495 http://dx.doi.org/10.3324/haematol.2022.281216 Text en Copyright© 2023 Ferrata Storti Foundation https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution Noncommercial License (by-nc 4.0) which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited. |
spellingShingle | Article - Acute Myeloid Leukemia Pratz, Keith W. Kaplan, Jason Levy, Moshe Bixby, Dale Burke, Patrick W. Erba, Harry Wise-Draper, Trisha M. Roboz, Gail J. Papadantonakis, Nikolaos Rajkhowa, Trivikram Hernandez, Daniela Dobler, Iwona Gregory, Richard C. Li, Cheryl Wang, Shining Stumpo, Kate Kannan, Karuppiah Miao, Harry Levis, Mark A phase Ib trial of mivavotinib (TAK-659), a dual SYK/FLT3 inhibitor, in patients with relapsed/refractory acute myeloid leukemia |
title | A phase Ib trial of mivavotinib (TAK-659), a dual SYK/FLT3 inhibitor, in patients with relapsed/refractory acute myeloid leukemia |
title_full | A phase Ib trial of mivavotinib (TAK-659), a dual SYK/FLT3 inhibitor, in patients with relapsed/refractory acute myeloid leukemia |
title_fullStr | A phase Ib trial of mivavotinib (TAK-659), a dual SYK/FLT3 inhibitor, in patients with relapsed/refractory acute myeloid leukemia |
title_full_unstemmed | A phase Ib trial of mivavotinib (TAK-659), a dual SYK/FLT3 inhibitor, in patients with relapsed/refractory acute myeloid leukemia |
title_short | A phase Ib trial of mivavotinib (TAK-659), a dual SYK/FLT3 inhibitor, in patients with relapsed/refractory acute myeloid leukemia |
title_sort | phase ib trial of mivavotinib (tak-659), a dual syk/flt3 inhibitor, in patients with relapsed/refractory acute myeloid leukemia |
topic | Article - Acute Myeloid Leukemia |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9973464/ https://www.ncbi.nlm.nih.gov/pubmed/36226495 http://dx.doi.org/10.3324/haematol.2022.281216 |
work_keys_str_mv | AT pratzkeithw aphaseibtrialofmivavotinibtak659adualsykflt3inhibitorinpatientswithrelapsedrefractoryacutemyeloidleukemia AT kaplanjason aphaseibtrialofmivavotinibtak659adualsykflt3inhibitorinpatientswithrelapsedrefractoryacutemyeloidleukemia AT levymoshe aphaseibtrialofmivavotinibtak659adualsykflt3inhibitorinpatientswithrelapsedrefractoryacutemyeloidleukemia AT bixbydale aphaseibtrialofmivavotinibtak659adualsykflt3inhibitorinpatientswithrelapsedrefractoryacutemyeloidleukemia AT burkepatrickw aphaseibtrialofmivavotinibtak659adualsykflt3inhibitorinpatientswithrelapsedrefractoryacutemyeloidleukemia AT erbaharry aphaseibtrialofmivavotinibtak659adualsykflt3inhibitorinpatientswithrelapsedrefractoryacutemyeloidleukemia AT wisedrapertrisham aphaseibtrialofmivavotinibtak659adualsykflt3inhibitorinpatientswithrelapsedrefractoryacutemyeloidleukemia AT robozgailj aphaseibtrialofmivavotinibtak659adualsykflt3inhibitorinpatientswithrelapsedrefractoryacutemyeloidleukemia AT papadantonakisnikolaos aphaseibtrialofmivavotinibtak659adualsykflt3inhibitorinpatientswithrelapsedrefractoryacutemyeloidleukemia AT rajkhowatrivikram aphaseibtrialofmivavotinibtak659adualsykflt3inhibitorinpatientswithrelapsedrefractoryacutemyeloidleukemia AT hernandezdaniela aphaseibtrialofmivavotinibtak659adualsykflt3inhibitorinpatientswithrelapsedrefractoryacutemyeloidleukemia AT dobleriwona aphaseibtrialofmivavotinibtak659adualsykflt3inhibitorinpatientswithrelapsedrefractoryacutemyeloidleukemia AT gregoryrichardc aphaseibtrialofmivavotinibtak659adualsykflt3inhibitorinpatientswithrelapsedrefractoryacutemyeloidleukemia AT licheryl aphaseibtrialofmivavotinibtak659adualsykflt3inhibitorinpatientswithrelapsedrefractoryacutemyeloidleukemia AT wangshining aphaseibtrialofmivavotinibtak659adualsykflt3inhibitorinpatientswithrelapsedrefractoryacutemyeloidleukemia AT stumpokate aphaseibtrialofmivavotinibtak659adualsykflt3inhibitorinpatientswithrelapsedrefractoryacutemyeloidleukemia AT kannankaruppiah aphaseibtrialofmivavotinibtak659adualsykflt3inhibitorinpatientswithrelapsedrefractoryacutemyeloidleukemia AT miaoharry aphaseibtrialofmivavotinibtak659adualsykflt3inhibitorinpatientswithrelapsedrefractoryacutemyeloidleukemia AT levismark aphaseibtrialofmivavotinibtak659adualsykflt3inhibitorinpatientswithrelapsedrefractoryacutemyeloidleukemia AT pratzkeithw phaseibtrialofmivavotinibtak659adualsykflt3inhibitorinpatientswithrelapsedrefractoryacutemyeloidleukemia AT kaplanjason phaseibtrialofmivavotinibtak659adualsykflt3inhibitorinpatientswithrelapsedrefractoryacutemyeloidleukemia AT levymoshe phaseibtrialofmivavotinibtak659adualsykflt3inhibitorinpatientswithrelapsedrefractoryacutemyeloidleukemia AT bixbydale phaseibtrialofmivavotinibtak659adualsykflt3inhibitorinpatientswithrelapsedrefractoryacutemyeloidleukemia AT burkepatrickw phaseibtrialofmivavotinibtak659adualsykflt3inhibitorinpatientswithrelapsedrefractoryacutemyeloidleukemia AT erbaharry phaseibtrialofmivavotinibtak659adualsykflt3inhibitorinpatientswithrelapsedrefractoryacutemyeloidleukemia AT wisedrapertrisham phaseibtrialofmivavotinibtak659adualsykflt3inhibitorinpatientswithrelapsedrefractoryacutemyeloidleukemia AT robozgailj phaseibtrialofmivavotinibtak659adualsykflt3inhibitorinpatientswithrelapsedrefractoryacutemyeloidleukemia AT papadantonakisnikolaos phaseibtrialofmivavotinibtak659adualsykflt3inhibitorinpatientswithrelapsedrefractoryacutemyeloidleukemia AT rajkhowatrivikram phaseibtrialofmivavotinibtak659adualsykflt3inhibitorinpatientswithrelapsedrefractoryacutemyeloidleukemia AT hernandezdaniela phaseibtrialofmivavotinibtak659adualsykflt3inhibitorinpatientswithrelapsedrefractoryacutemyeloidleukemia AT dobleriwona phaseibtrialofmivavotinibtak659adualsykflt3inhibitorinpatientswithrelapsedrefractoryacutemyeloidleukemia AT gregoryrichardc phaseibtrialofmivavotinibtak659adualsykflt3inhibitorinpatientswithrelapsedrefractoryacutemyeloidleukemia AT licheryl phaseibtrialofmivavotinibtak659adualsykflt3inhibitorinpatientswithrelapsedrefractoryacutemyeloidleukemia AT wangshining phaseibtrialofmivavotinibtak659adualsykflt3inhibitorinpatientswithrelapsedrefractoryacutemyeloidleukemia AT stumpokate phaseibtrialofmivavotinibtak659adualsykflt3inhibitorinpatientswithrelapsedrefractoryacutemyeloidleukemia AT kannankaruppiah phaseibtrialofmivavotinibtak659adualsykflt3inhibitorinpatientswithrelapsedrefractoryacutemyeloidleukemia AT miaoharry phaseibtrialofmivavotinibtak659adualsykflt3inhibitorinpatientswithrelapsedrefractoryacutemyeloidleukemia AT levismark phaseibtrialofmivavotinibtak659adualsykflt3inhibitorinpatientswithrelapsedrefractoryacutemyeloidleukemia |